1088714-08-2

Upstream product

• 1023742-62-2 ethyl 3-((4-bromo-2-fluorophenyl)amino)-3-iminopropanoate 
• 367-24-8 4-bromo-2-fluoroaniline 
• 1088714-05-9 ethyl 2-(4-bromo-2-fluorophenylamino)-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 
• 1088714-34-4 ethyl 3-((4-bromo-2-fluorophenyl)amino)-3-iminopropanoate hydrochloride 
• 1088714-06-0 ethyl 2-(4-bromo-2-fluorophenylamino)-1-methyl-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 
• 1088714-07-1 2-(4-bromo-2-fluorophenylamino)-1-methyl-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid 
• 774172-83-7 C₃H₉NO₃ 

Relevant academic research and scientific papers

Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy

The structure-based design, synthesis, and biological evaluation of two novel series of potent and selective MEK kinase inhibitors are described herein. The elaboration of a lead pyrrole derivative to a bicyclic dihydroindolone core provided compounds wit

MAPK/ERK KINASE INHIBITORS

Compounds are provided for inhibition of MEK that comprise: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making